Bruce E. Sands, MD, MS, FACG

Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Poster(s):

• P3189 - Maintenance of Endoscopic and Histologic Efficacy With Guselkumab for Ulcerative Colitis at Week 92 of the QUASAR Long-Term Extension Study
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT

• P3190 - Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Extended Induction Results From the LUCENT-3 Open-Label Study
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT

• P3191 - Long-Term Efficacy of Etrasimod in Patients With Ulcerative Colitis: 2-Year Outcomes From the ELEVATE Open-Label Extension
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT

• P3192 - Effects of Subcutaneous Guselkumab Induction and Maintenance on Histologic Outcomes in Patients With Moderately to Severely Active Crohn’s Disease in GRAVITI, a Phase 3 Double-Blind, Placebo-Controlled, Treat-Through Study
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT

• P3193 - Intravenous and Subcutaneous Guselkumab Induction Therapy Are Both Efficacious in Crohn’s Disease Patients With High Baseline Disease Severity: Results at Week 12 From the Phase 3 GALAXI and GRAVITI Studies
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT

• P3194 - Efficacy and Safety of Tulisokibart Maintenance Treatment in Tulisokibart Induction, Re-induction, and Delayed Induction Responders: Open-Label Extension of the ARTEMIS-UC Trial in Patients With Ulcerative Colitis
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT

• P3195 - Treat-to-Target Gaps in Crohn’s Disease: Insights From Real-World Practice
  Monday, October 27, 2025

  10:30 AM - 4:00 PM MT